Recognized for Advancing Secure, Governed AI Adoption in the Enterprise
JAKARTA, Indonesia, Oct. 7, 2026 /PRNewswire/ -- HEARTBOT AI Inc., the company behind AnyInsight.ai, has received the ASOCIO Global Business Service Award at the ASOCIO Digital & AI Summit 2026, held on October 6 at Swissôtel Jakarta PIK Avenue in Jakarta, Indonesia.
The award recognizes organizations demonstrating excellence in technology-enabled business services, operational innovation, digital transformation, and service delivery. HEARTBOT AI Inc. CEO Nathan Yen represented the company at the ceremony, where the award was presented by ASOCIO Chairman Stan Singh-Jit and members of the award evaluation committee.
Governance Takes Center Stage as AI Enters the Enterprise
Generative AI is moving beyond individual experimentation into core business workflows and automated processes. As adoption expands across teams, the central question for enterprises is shifting from which AI tools to use toward how AI is governed across the organization — who can access it, how its activity is monitored, and how risk is managed as it touches more of daily operations.
Regulation is accelerating this shift. The EU AI Act already imposes active obligations on organizations that develop or deploy AI: transparency requirements took effect in August 2026, and obligations on general-purpose AI models have applied since August 2025, with further risk-based requirements phasing in through 2027 and 2028, while GDPR obligations and penalties remain unaffected. For enterprises operating internationally, these requirements are shaping how AI is adopted today, not a distant compliance milestone.
AnyInsight.ai is built for this environment, bringing AI models, agents, workflows, and automation together with identity and access management and a semantic firewall in a single enterprise platform, organized into separate workspaces by department, project, or client — so governance scales alongside adoption rather than trailing behind it.
Productivity, Built on a Foundation of Governance
"As AI becomes part of how work gets done, organizations need more than productivity gains — they need clear oversight into how AI is accessed, used, and governed across the business," said Nathan Yen, CEO of HEARTBOT AI Inc.
"Governance has to grow alongside adoption. As companies extend AI into more workflows and automated processes, they need identity and access management, real-time monitoring, and a firewall that inspects AI activity as it happens — not after the fact."
AnyInsight.ai's governance and security layer includes three-tier identity and access management with role-based permissions, a semantic GenAI firewall that inspects prompts, files, and connector activity in real time, an immutable activity log, and an auditor role with full visibility and no edit rights. The platform also connects 20+ large language models, 350+ pre-built and custom agents, and 500+ application connectors into enterprise workflows and automated processes.
This reflects a broader shift in enterprise AI adoption — from isolated use of individual AI tools toward AI that is integrated into organizational workflows, monitored continuously, and governed from the start.
About HEARTBOT AI Inc.
HEARTBOT AI Inc. develops enterprise AI solutions focused on governance, security, and compliant AI adoption for organizations operating under evolving global regulation.
The company holds ISO 27001 certification for information security management and continues to align its platform with evolving global AI regulation, including the EU AI Act.
Its flagship platform, AnyInsight.ai, unifies AI models, agents, knowledge, workflows, and automation with identity and access management, a semantic firewall, and activity monitoring — helping enterprises scale AI adoption while keeping governance built in from the start.
Explore AnyInsight.ai
Learn More About HEARTBOT AI
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
AnyInsight.ai Wins ASOCIO Global Business Service Award
- Participates in CPHI Milan 2026, Expanding Manufacturing AX Reach in Pharma
- Showcasing key solutions for factory design, production operations, and quality management using the theme "Autonomous Factory in Pharma"
SEOUL, South Korea and MILAN, Oct. 7, 2026 /PRNewswire/ -- LG CNS, a leading AI Transformation company in Korea, is expanding its manufacturing AX business with a showcase of pharma-specific smart factory technologies at CPHI Milan 2026, the world's largest pharmaceutical and biotech exhibition.
The Convention on Pharmaceutical Ingredients (CPHI) is a global pharma and biotech trade show held at various global venues throughout the year, including the United States, Europe, Asia, and the Middle East. The Milan show is CPHI's flagship event, drawing around 60,000 visitors and roughly 3,000 companies from more than 160 countries. It is widely regarded as the premier stage on which the latest technologies and trends of the global pharma and biotech industry converge. LG CNS is the only Korean company participating in the newly created "AI & Tech" zone this year.
The theme of LG CNS's booth is Autonomous Factory in Pharma and is designed around the introduction of three smart factory solutions connecting factory design, production operations, and quality management. Pharma and biotech companies building or expanding production facilities can adopt these solutions across the entire process, from factory construction through ongoing operations.
For the factory design stage, LG CNS presents Factova Worldworks, a digital twin-based virtual validation simulator that recreates the actual factory in a virtual space. It models the factory layout in 3D to review the optimal placement of pharmaceutical manufacturing equipment, the routes that workers will take within the planned factory, and the path along which raw materials are to be transferred. Pharmaceutical factories separate zones such as cleanrooms and production areas to prevent raw material contamination. Worker access permissions also differ by zone, so planning their routes carefully in advance is more essential than in general manufacturing factories.
Factova Control is a data standardization and equipment control solution for the production operations stage. It automatically converts process data such as raw material ID numbers and formulations into a unified format, unit, and notation so that every manufacturing step works from consistent data. This lets customers respond immediately when adding new equipment or changing process workflows. The solution also detects equipment anomalies and predicts failures, using AI to analyze electrical current, temperature, and vibration data in real time to flag early warning signs.
The quality management solution analyzes data such as production volume, raw material temperature changes, and equipment operation history to check for product quality issues. It also supports everything from root-cause investigations to follow-up actions when problems are identified. Notably, when it detects an anomaly midway through a process, it immediately calculates alternatives to resolve the issue and then applies them to the next production step, proactively preventing defective products.
An AI agent trained on quality data also drafts the Annual Product Quality Review (APQR). Pharma and biotech companies conduct annual quality reviews to comply with each country's Good Manufacturing Practice (GMP) regulations and document the results in the APQR. Previously, staff collected, analyzed, and verified the required data by hand, a process that could take months. LG CNS has automated the entire process with AI, cutting the time required by more than 90%.
"The manufacturing AX solutions we are showcasing at this exhibition are tailored to pharma so we can support our pharma and biotech customers with intelligent automation across the entire process, from factory design to quality management," said Eddie Jang, Head of the Chemical/Battery Division at LG CNS. "As a turnkey provider covering every area of manufacturing, we will continue to use our advanced solutions to address the challenges of developing pharmaceutical manufacturing sites, which demand high precision and strict quality standards, and help customers produce medicines in a more automated and efficient way."
About LG CNS
LG CNS is a leading Korean AX (AI Transformation) company that continues to pioneer various emerging technologies, including AI, robotics, cloud computing, data center, and smart engineering, encompassing smart factories and smart logistics, as well as digital marketing. The company also leads the market through innovative system integration (SI) and system management (SM) capabilities across finance, manufacturing, the public sector, and various other industries. For more information, please visit https://www.lgcns.com.
SEOUL, South Korea and MILAN, Oct. 7, 2026 /PRNewswire/ -- LG CNS, a leading AI Transformation company in Korea, is expanding its manufacturing AX business with a showcase of pharma-specific smart factory technologies at CPHI Milan 2026, the world's largest pharmaceutical and biotech exhibition.
The Convention on Pharmaceutical Ingredients (CPHI) is a global pharma and biotech trade show held at various global venues throughout the year, including the United States, Europe, Asia, and the Middle East. The Milan show is CPHI's flagship event, drawing around 60,000 visitors and roughly 3,000 companies from more than 160 countries. It is widely regarded as the premier stage on which the latest technologies and trends of the global pharma and biotech industry converge. LG CNS is the only Korean company participating in the newly created "AI & Tech" zone this year.
The theme of LG CNS's booth is Autonomous Factory in Pharma and is designed around the introduction of three smart factory solutions connecting factory design, production operations, and quality management. Pharma and biotech companies building or expanding production facilities can adopt these solutions across the entire process, from factory construction through ongoing operations.
For the factory design stage, LG CNS presents Factova Worldworks, a digital twin-based virtual validation simulator that recreates the actual factory in a virtual space. It models the factory layout in 3D to review the optimal placement of pharmaceutical manufacturing equipment, the routes that workers will take within the planned factory, and the path along which raw materials are to be transferred. Pharmaceutical factories separate zones such as cleanrooms and production areas to prevent raw material contamination. Worker access permissions also differ by zone, so planning their routes carefully in advance is more essential than in general manufacturing factories.
Factova Control is a data standardization and equipment control solution for the production operations stage. It automatically converts process data such as raw material ID numbers and formulations into a unified format, unit, and notation so that every manufacturing step works from consistent data. This lets customers respond immediately when adding new equipment or changing process workflows. The solution also detects equipment anomalies and predicts failures, using AI to analyze electrical current, temperature, and vibration data in real time to flag early warning signs.
The quality management solution analyzes data such as production volume, raw material temperature changes, and equipment operation history to check for product quality issues. It also supports everything from root-cause investigations to follow-up actions when problems are identified. Notably, when it detects an anomaly midway through a process, it immediately calculates alternatives to resolve the issue and then applies them to the next production step, proactively preventing defective products.
An AI agent trained on quality data also drafts the Annual Product Quality Review (APQR). Pharma and biotech companies conduct annual quality reviews to comply with each country's Good Manufacturing Practice (GMP) regulations and document the results in the APQR. Previously, staff collected, analyzed, and verified the required data by hand, a process that could take months. LG CNS has automated the entire process with AI, cutting the time required by more than 90%.
"The manufacturing AX solutions we are showcasing at this exhibition are tailored to pharma so we can support our pharma and biotech customers with intelligent automation across the entire process, from factory design to quality management," said Eddie Jang, Head of the Chemical/Battery Division at LG CNS. "As a turnkey provider covering every area of manufacturing, we will continue to use our advanced solutions to address the challenges of developing pharmaceutical manufacturing sites, which demand high precision and strict quality standards, and help customers produce medicines in a more automated and efficient way."
About LG CNS
LG CNS is a leading Korean AX (AI Transformation) company that continues to pioneer various emerging technologies, including AI, robotics, cloud computing, data center, and smart engineering, encompassing smart factories and smart logistics, as well as digital marketing. The company also leads the market through innovative system integration (SI) and system management (SM) capabilities across finance, manufacturing, the public sector, and various other industries. For more information, please visit https://www.lgcns.com.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
LG CNS Showcases Pharma-Specific Manufacturing AX at World's Largest Pharma-Biotech Show
